Literature DB >> 26530654

Which patients need critical care intervention after total joint arthroplasty? : a prospective study of factors associated with the need for intensive care following surgery.

P M Courtney1, C M Melnic1, J Gutsche1, E L Hume1, G-C Lee1.   

Abstract

Older patients with multiple medical co-morbidities are increasingly being offered and undergoing total joint arthroplasty (TJA). These patients are more likely to require intensive care support, following surgery. We prospectively evaluated the need for intensive care admission and intervention in a consecutive series of 738 patients undergoing elective hip and knee arthroplasty procedures. The mean age was 60.6 years (18 to 91; 440 women, 298 men. Risk factors, correlating with the need for critical care intervention, according to published guidelines, were analysed to identify high-risk patients who would benefit from post-operative critical care monitoring. A total of 50 patients (6.7%) in our series required critical care level interventions during their hospital stay. Six independent multivariate clinical predictors were identified (p < 0.001) including a history of congestive heart failure (odds ratio (OR) 24.26, 95% confidence interval (CI) 9.51 to 61.91), estimated blood loss > 1000 mL (OR 17.36, 95% CI 5.36 to 56.19), chronic obstructive pulmonary disease (13.90, 95% CI 4.78 to 40.36), intra-operative use of vasopressors (OR 8.10, 95% CI 3.23 to 20.27), revision hip arthroplasty (OR 2.71, 95% CI 1.04 to 7.04) and body mass index > 35 kg/m(2) (OR 2.70, 95% CI 123 to 5.94). The model was then validated against an independent, previously published data set of 1594 consecutive patients. The use of this risk stratification model can be helpful in predicting which high-risk patients would benefit from a higher level of monitoring and care after elective TJA and aid hospitals in allocating precious critical care resources. ©2015 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  complications; critical care; total hip arthroplasty; total knee arthroplasty

Mesh:

Year:  2015        PMID: 26530654     DOI: 10.1302/0301-620X.97B11.35813

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  7 in total

1.  Editor's Spotlight/Take 5: What are the Risk Factors for Cerebrovascular Accidents After Elective Orthopaedic Surgery?

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2016-01-04       Impact factor: 4.176

2.  Defining growth potential and barriers to same day discharge total knee arthroplasty.

Authors:  Megan E Gillis; Johanna Dobransky; Geoffrey F Dervin
Journal:  Int Orthop       Date:  2018-09-07       Impact factor: 3.075

3.  The Impact of Medical Comorbidities on Primary Total Knee Arthroplasty Reimbursements.

Authors:  Karim G Sabeh; Samuel Rosas; Leonard T Buller; Andrew A Freiberg; Cynthia L Emory; Martin W Roche
Journal:  J Knee Surg       Date:  2018-05-23       Impact factor: 2.501

4.  Complications after total knee replacement in patients with chronic obstructive pulmonary disease: A nationwide case-control study.

Authors:  Kuang-Ming Liao; Hsueh-Yi Lu
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

5.  Response to Letter to the Editor Titled "Risk Modeling for Unplanned Intensive Care Unit (ICU) Admission".

Authors:  Kamolsak Sukhonthamarn; Matthew J Grosso; Javad Parvizi
Journal:  J Arthroplasty       Date:  2020-05-08       Impact factor: 4.757

6.  Total knee arthroplasty improves the quality-adjusted life years in patients who exceeded their estimated life expectancy.

Authors:  Michele Palazzuolo; Alexander Antoniadis; Jaad Mahlouly; Julien Wegrzyn
Journal:  Int Orthop       Date:  2021-01-15       Impact factor: 3.075

7.  Practices in Triage and Transfer of Critically Ill Patients: A Qualitative Systematic Review of Selection Criteria.

Authors:  Joseph Dahine; Paul C Hébert; Daniela Ziegler; Noémie Chenail; Nicolay Ferrari; Réjean Hébert
Journal:  Crit Care Med       Date:  2020-11       Impact factor: 9.296

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.